Peptides News and Research

RSS

New peptide-like molecules could treat herpes, COVID-19, and the common cold

Among the powerful biochemicals of the human immune system, peptides are one of the best.

24 May 2021

Computationally designed peptide blocks the entry of SARS-CoV, SARS-CoV-2, and MERS-CoV

In order to develop effective antiviral drugs, scientists design active molecules based on their structures that can prevent or disrupt the specific viral-receptor binding - this is an effective strategy to prevent the virus from entering the host.

23 May 2021

Researchers speculate the low prevalence of COVID-19 in Japan

Protective immune memory--through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells--can be induced by identical but also by related viruses.

20 May 2021

New peptides allow cannabis-derived drugs to fight pain in mice without side effects

An international team, led by researchers from Pompeu Fabra University (UPF) in Barcelona, Spain, David Andreu and Rafael Maldonado, has developed a peptides family that allows delta-9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, to fight pain in mice without side effects.

20 May 2021

Pirfenidone significantly reduces a marker of heart muscle scarring

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.

18 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

In a paper published on the bioRxiv* preprint server, researchers report new monoclonal antibodies that target the S2 subunit and that have broad neutralization activity against several betacoronaviruses.

13 May 2021

New peptide could allow cannabis to fight pain without side effects

Many people live with chronic pain, and in some cases, cannabis can provide relief. But the drug also can significantly impact memory and other cognitive functions.

12 May 2021

Researchers develop a hairpin-shaped bicyclic peptide to fight cancer

The inhibition of pathological protein-protein interactions is a promising approach for treating a large number of diseases, including many forms of cancer.

12 May 2021

CNIO researchers unravel why motor neurons die in ALS patients

In Amyotrophic Lateral Sclerosis (ALS), the progressive death of neurons that control body movement leads to paralysis of muscles in the limbs and gradually of the whole body, which ultimately makes it impossible to breathe. ALS is currently untreatable, and its cause is unknown.

12 May 2021

Personalized vaccine can provide effective immunization against cancer

Marie-Claude Bourgeois-Daigneault and her team at the CRCHUM are using mice to show how a combination of peptides and oncolytic viruses, used as an adjuvant, can provide effective immunization against cancer.

11 May 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

A new study released as a bioRxiv* preprint tried to establish how tissues such as the upper respiratory tract (URT) – which harbor the virus and often act as the point of entry – are difficult to access for routine testing, but are responsive to vaccination.

11 May 2021

Specially designed hydrogel offers great hope for combating antibiotic-resistant bacteria

Researchers at Chalmers University of Technology, Sweden, have developed a new material that prevents infections in wounds - a specially designed hydrogel, that works against all types of bacteria, including antibiotic-resistant ones.

11 May 2021

Natural products a rich source for novel antiviral compounds

In a recent review in the journal Viruses, researchers look at natural products that can be identified as potential alternative antiviral agents. The reviewers discussed the antiviral activities of several natural products towards DNA and RNA viruses with an analytical approach. The researchers detailed the cellular/viral targets of the active molecules and their impact on the infection and viral replication cycle.

10 May 2021

Researchers improve method to inhibit viruses that cause childhood respiratory infections

By engineering a short chunk of protein, or peptide, that can prevent the attachment of human parainfluenza viruses to cells, researchers have improved a method in rodent models intended to help keep children healthy.

10 May 2021

Cryptic pocket on the surface of SARS-CoV-2 may be a promising treatment target

In a new study currently available on the bioRxiv* preprint server, a multinational group of researchers modeled an entire membrane-embedded spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlighted the potential of a specific mapping approach for unveiling cryptic, potentially druggable pockets on the viral surface.

7 May 2021

Transplant recipients with COVID-19 may show lower cellular and antibody immune responses

Transplant patients are typically on chronic immunosuppression, making them automatically more vulnerable to infection with SARS-CoV-2, the agent responsible for the loss of over three million lives in the current COVID-19 pandemic. A new study discusses evidence for subnormal immune responses following COVID-19 in this population.

6 May 2021

Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Researchers in the United States have shown that prior Measles-Mumps-Rubella (MMR) or Tetanus-Diphtheria-pertussis (Tdap) vaccination may reduce the risk of severe outcomes in patients with coronavirus disease 2019 (COVID-19).

5 May 2021

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Researchers in the United States have shown that the Pfizer/BioNTech and Moderna messenger RNA (mRNA) vaccines are effective at generating T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021